Preventive Management of Recurrent Paroxysmal Supraventricular Tachycardia
Catheter ablation is the recommended first-line therapy for preventing recurrent PSVT, with success rates of 93-95% and should be offered to all patients with recurrent symptomatic episodes 1, 2.
Investigations to Send
Before initiating any preventive therapy, obtain the following:
- 12-lead ECG during sinus rhythm - Look specifically for pre-excitation (delta waves indicating WPW syndrome), as this fundamentally changes management
- Ambulatory monitoring (Holter or event recorder) if diagnosis not yet confirmed on ECG during tachycardia
- Echocardiogram - Rule out structural heart disease or tachycardia-mediated cardiomyopathy (occurs in ~1% of patients) 2
- Thyroid function tests and serum magnesium - Especially if multifocal atrial tachycardia suspected
- Baseline ECG with QTc measurement - Essential before starting any antiarrhythmic medication
Preventive Medication Algorithm
If Patient Has Pre-excitation on ECG (WPW Syndrome):
DO NOT use beta-blockers, diltiazem, verapamil, or digoxin - these can accelerate conduction through the accessory pathway and precipitate life-threatening ventricular arrhythmias 1.
Medication options (in order of preference):
Flecainide or propafenone (Class I recommendation) - 85-90% effective, but ONLY if no structural heart disease or ischemic heart disease. Side effects occur in 60% of patients 1
Dofetilide or sotalol (Class IIa) - Can be used if structural heart disease present. Requires inpatient initiation with serial ECGs due to QT prolongation risk 1
Amiodarone (Class IIb) - Reserved for refractory cases due to significant long-term toxicity 1
If Patient Has NO Pre-excitation (Concealed Pathway or AVNRT):
First-line medications (Class I recommendation):
- Beta-blockers (metoprolol) OR
- Diltiazem OR
- Verapamil
These are approximately 50% effective for preventing recurrence and have favorable side effect profiles 1, 3.
Special Considerations:
Avoid beta-blockers if:
- Severe bronchospastic pulmonary disease
- Acute decompensated heart failure
- Severe conduction abnormalities or sinus node dysfunction
Avoid calcium channel blockers if:
- Severe conduction abnormalities
- Sinus node dysfunction
- Acute decompensated heart failure
Critical Pitfalls to Avoid
Never give AV nodal blocking agents (beta-blockers, calcium channel blockers, digoxin, or IV amiodarone) to patients with pre-excited atrial fibrillation - This can be lethal 1
Do not use Class Ic agents (flecainide/propafenone) in patients with any structural heart disease or coronary disease - Risk of proarrhythmic ventricular tachycardia 1
Always initiate dofetilide or sotalol as an inpatient with continuous monitoring due to torsades de pointes risk 1
Why Catheter Ablation Should Be First-Line
The 2015 ACC/AHA/HRS guidelines give catheter ablation a Class I recommendation with success rates of 93-95% and only 3% major complication risk 1. More recent data from 2024 shows even higher success rates of 94.3-98.5% 2. Medications are only ~50% effective and carry ongoing side effects, while ablation offers potential cure 1, 2.
The evidence strongly favors discussing ablation with all symptomatic patients before committing to long-term pharmacotherapy, as the effectiveness of medications is limited and the evidence supporting their long-term use is weak 2.